HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Toxicology Forum

This article was originally published in The Rose Sheet

Executive Summary

Nonprofit organization "devoted to conducting open dialogues among various segments of society concerned with problems in toxicology" will hold its 35 annual summer meeting July 12-16 at the Given Institute in Aspen, Colorado. Research Institute for Fragrance Materials' Anne Marie Api, VP of human health sciences, will chair half-day session entitled "Quantitative Risk Assessment for Dermal Sensitization: What's An Acceptable Exposure?" Panel discussion will involve Procter & Gamble's Carsten Goebel, who will speak on the scientific principles of dermal sensitization risk assessment, as well as dermatologist Donald Belsito of the University of Missouri, who will provide a medical perspective, and the Consumer Products Safety Commission's Joanna Matheson, who will offer a regulatory view. Linda Katz from FDA and Alan Andersen, scientific director of the Cosmetic Ingredient Review, also will participate. Other sessions planned for the Toxicology Forum's July meeting include "Manufactured Nanoscale Materials: Carbon Nanotube Toxicology," "NAS Report on Phthalates and Cumulative Risk Assessment: The Task Ahead," and "Can Carcinogenicity Be Predicted by 6- or 12-Month in vivo Toxicology Data? Results from Analysis of a New Pharmaceutical Database.

You may also be interested in...



Impella Safety Update: Data Supports Pump For Qualified Patients

Updated data from a postmarket study of Abiomed’s Impella RP right-heart pump further supports the device’s safety for a specific patient population.

Quality, Safety, MDSAP A Focus For Medtech In New USMCA Trade Agreement

The new US-Mexico-Canada (USMCA) trade agreement includes language on enhancing regulatory compatibility between the three countries by recognizing quality systems audits performed under the Medical Device Single Audit Program (MDSAP). It also stipulates that each trading partner “consider its resources and technical capacity” in ensuring the safety, effectiveness and quality of devices – and more. Medtech industry advocacy group AdvaMed is praising the deal, reached by the three countries on 10 December.

Novo Nordisk Targets Smart Insulin, Stem Cell-Therapies

Novo Nordisk’s CEO talks to Scrip about the promise of glucose-responsive insulin, stem cell therapy, and a diabetes landscape without Sanofi.

UsernamePublicRestriction

Register

RS016224

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel